(Q35999576)

11 August 2017

1 reference

title

Abacavir plus lamivudine: a review of their combined use in the management of HIV infection (English)

1 reference

11 August 2017

1 reference

1 reference

2

Lesley J Scott

1 reference

11 August 2017

Toni M Dando

1

1 reference

11 August 2017

language of work or name

1 reference

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

65

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

285-302

1 reference

Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates

11 August 2017

cites work

1 reference

12 December 2020

Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial

1 reference

12 December 2020

Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.

1 reference

12 December 2020

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial

1 reference

12 December 2020

Abacavir: a review of its clinical potential in patients with HIV infection

1 reference

12 December 2020

1 reference

12 December 2020

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

12 December 2020

Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients

1 reference

12 December 2020

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

12 December 2020

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

1 reference

12 December 2020

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

12 December 2020

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

1 reference

12 December 2020

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection

1 reference

12 December 2020

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

1 reference

12 December 2020

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).

1 reference

12 December 2020

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

12 December 2020

Lamivudine/zidovudine/abacavir: triple combination tablet

1 reference

12 December 2020

Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase

1 reference

12 December 2020

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

1 reference

12 December 2020

Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.

1 reference

12 December 2020

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations

1 reference

12 December 2020

Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily

1 reference

12 December 2020

10.2165/00003495-200565020-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1026738356

0 references

1 reference